Thermo Fisher Scientific (NYSE:TMO) Price Target Raised to $775.00

Posted by Francis Steltz on Oct 25th, 2026

Thermo Fisher Scientific (NYSE:TMO – Free Report) had its price target hoisted by Stifel Nicolaus from $650.00 to $775.00 in a report released on Thursday, MarketBeat.com reports. The brokerage currently has a buy rating on the medical research company’s stock.

A number of other research analysts also recently commented on the stock. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $650.00 to $730.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Barclays upped their target price on shares of Thermo Fisher Scientific from $750.00 to $775.00 and gave the company an “overweight” rating in a report on Thursday. BMO Capital Markets downgraded shares of Thermo Fisher Scientific to a “market perform” rating in a research note on Wednesday, September 9th. Scotiabank started coverage on Thermo Fisher Scientific in a report on Wednesday, September 9th. They set an “outperform” rating for the company. Finally, HSBC raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 1st. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $681.00.

Read Our Latest Research Report on TMO

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $673.97 on Thursday. Thermo Fisher Scientific has a 1-year low of $435.27 and a 1-year high of $705.78. The company has a current ratio of 1.81, a quick ratio of 1.18 and a debt-to-equity ratio of 0.71. The firm has a fifty day simple moving average of $645.72 and a 200 day simple moving average of $554.80. The stock has a market capitalization of $249.20 billion, a PE ratio of 35.55, a P/E/G ratio of 2.80 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28. The business had revenue of $12.14 billion for the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the company earned $5.79 earnings per share. On average, research analysts expect that Thermo Fisher Scientific will post 25.23 EPS for the current fiscal year.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph Holmes sold 420 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at $1,734,546.46. This represents a 12.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares of the company’s stock, valued at $13,927,815. This trade represents a 1.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is currently owned by insiders.

Institutional Trading of Thermo Fisher Scientific

Hedge funds have recently added to or reduced their stakes in the company. Legacy Wealth Managment LLC ID grew its holdings in Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after buying an additional 22 shares in the last quarter. Kilter Group LLC acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth $25,000. Allied Private Wealth LLC acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth $26,000. MBM Wealth Consultants LLC bought a new stake in shares of Thermo Fisher Scientific in the first quarter valued at about $29,000. Finally, Pingora Partners LLC bought a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $30,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

Positive Sentiment: Q3 earnings and revenue beat expectations. Thermo Fisher reported adjusted earnings of $6.68 per share versus the $6.40 consensus, while revenue rose 9.1% year over year to $12.14 billion, topping estimates of $11.95 billion. TMO Q3 deep dive: pharma demand, AI integration, and end-market recovery drive momentum
Positive Sentiment: Analysts raised their valuation targets. TD Cowen increased its target to $810 and maintained a buy rating, while Stifel raised its target to $775 and Baird lifted its target to $756 with an outperform rating. These revisions imply meaningful upside from recent trading levels. TD Cowen analyst ratings
Positive Sentiment: Improving end markets support the growth outlook. Investor commentary highlighted a broad-based recovery across life-science markets, including pharmaceutical demand, AI-related applications and other research tools. Erste Group also modestly raised its FY2027 EPS estimate to $27.58 from $27.51. Thermo Fisher benefits on broad-based recovery
Neutral Sentiment: Secular market growth provides a longer-term tailwind. Industry forecasts call for strong expansion in next-generation sequencing kits and peptide synthesis, markets in which Thermo Fisher participates, although these reports do not directly change near-term earnings. NGS kits market forecast
Negative Sentiment: Options activity signals caution. Heavy put-option buying indicates that some traders are hedging against, or positioning for, a pullback. The muted reaction to the earnings beat may also reflect elevated expectations and a relatively rich valuation. Thermo Fisher stock sees heavy put option buying

About Thermo Fisher Scientific

(Get Free Report)

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.